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Abstract
While the median survival in patients with glioblastoma
has not improved significantly over the past decade,
aggressive attempts have been made on palliation and
improving quality of life in these patients. A confluence of
two debilitating pathologies which massively distorts the
normal day-to-day functioning of the patients who
experience it, seizures in glioblastoma patients portends a
poor prognosis. There exists a paucity of reported seizure
outcomes after glioblastoma treatment in neurosurgical
literature. Herein we present a review examining post-
operative seizure control in patients with glioblastoma. 
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Introduction
Glioblastoma is the most frequent primary brain tumour in
adults, and has one of the poorest prognoses among all
brain tumours.1,2 Despite advancement in the field of
medical and surgical neuro-oncology, the median survival
has constantly remained below 2 years for the past
decade.3,4 This already grim outlook is further aggravated
by the presence of seizures in patients with glioblastoma,
which negatively impact the patients’ physical, cognitive,
psychological, and social well-being.5
Seizures have been reported to occur in 30 - 62% patients
with glioblastoma, with one-third occurring post-
operatively.1,5-7 The pathogenesis of tumour-related
seizures may involve a deficiency of gamma-aminobutyric
acid–mediated inhibition, but this remains largely
understudied.6 Seizure recurrence or worsening seizure
control may be associated with tumour molecular genetic
markers, extent of resection, and pharmaco-resistance to
treatment with first-line anti-epileptic drugs (AEDs).4,6,7
Although tumour related epilepsy (TRE) in patients with
glioblastoma has become an important concentration for
research, aiming to ameliorate the quality of life of these
patients in the face of a dismal survival outcome, evidence
on seizure control, and therein, improved outcomes,
remain sufficiently low. Here we have reviewed the
literature on seizure control in patients after glioblastoma
resection.
Review of Literature
We entered the keywords on PubMed and Google scholar
database and reviewed all the relevant studies. Telfeian et
al., retrospectively analyzed 72 patients in 2001,
undergoing craniotomy and palliative resection for
glioblastoma at their center, out of whom 17 had post-
operative seizures. Factors evaluated for association with
the risk of postoperative seizures included age, sex, tumour
size, tumour location, adjuvant therapy, postoperative
complications, and a history of preoperative seizures. All
except one patient with pre- and post-operative
convulsions had their first postoperative seizure while still
on AEDs. It was also observed that patients with no history
of  pre-operative seizures experienced seizures post-
operatively secondary to withdrawal from AEDs. Smaller
tumour size and frontal resection were associated with an
increased risk of postoperative seizures (Figure 1 and 2).2
Early recognition of factors associated with prolonged
seizure control may help guide timely and strategic
therapeutic interventions aimed at improving the quality
of life for patients with high grade astrocytoma.3 In 2009,
Chaichana et al., retrospectively reviewed 648 patients who
underwent primary resection of a hemispheric anaplastic
astrocytoma (AA) (n=143) or glioblastoma (n=505) at their
center. The patients were evaluated for the effects of
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Figure-1: Axial section of T2-weighted image of a 24 years old female patient who
had presented with seizures. It is showing a predominantly cystic lesion
in the right temporal lobe with surrounding oedema.
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surgery on seizure outcomes, and factors associated with
prolonged seizure control. Of those who presented with
seizures (n=153), outcome 12 months after surgery was
Engel Class I (seizure free) in 77%, Class II (rare seizures) in
12%, Class III (meaningful improvement) in 6%, and Class
IV (no improvement) in 5%. Increased Karnofsky
Performance Scale (KPS) score was significantly associated
with prolonged seizure control, while uncontrolled pre-
operative seizures and parietal lobe involvement were
statistically significant for poor seizure outcomes in these
patients. The authors also reported an independent
association of seizure recurrence with tumour recurrence
(p=0.006) in patients who had achieved postoperative
seizure control previously.3
Kerkhof et al., in 2013, retrospectively examined the
efficacy of valproic acid (VPA) and levetiracetam (LEV),
alone and as poly-therapy, on seizure control in 291
patients with glioblastoma. Seizure freedom was initially
achieved in 41% patients on VPA, 43.3% patients on LEV,
and 76.7% on VPA/LEV polytherapy. At the end of the 
6-month follow-up, 77.8% of the patients on VPA alone,
69.5% on LEV alone, and in 60.3% on VPA/LEV dual therapy
(with ongoing seizures on monotherapy) had achieved
complete seizure control. Owing to the decreased total
dosages of AEDs required for a similar or better antiseizure
effect, and hence, reduced drug toxicity, the authors
concluded that synergistic co-therapy with LEV was
superior to monotherapy, especially for achieving
prolonged seizure control.1 But later in 2015, Ening et al.,
suggested better seizure outcomes with monotherapy,
owing to higher patient compliance.8 Neal et al., suggested
benefit in therapies targeting glutamate in TRE.9 In 2016,
they retrospectively evaluated the impact of peri-tumoural
and/or tumoural glutamate on postoperative seizures in a
cohort of patients with grade 2 to grade 4 supra-tentorial
gliomas. In a subgroup analysis of 81 glioblastoma patients
receiving adjunct chemotherapy, peritumoural glutamate
concentration was significantly associated with time to first
post-operative seizure (HR 3.10, CI 1.20–7.97) p=0.02, and
hence, shorter periods of post-operative seizure freedom.9
In 2019, Feyissa et al., analyzed a single-center
retrospective cohort of 68 patients with gliomas, out of
which 31 had glioblastoma. Of the total, 31 patients
developed post-operative seizures, with median seizure
freedom duration of 10.5 months. The authors reported
that IDH1 mutation (p=0.035) and MGMT gene promotor
methylation (p=0.032) conferred a significant benefit in
post-operative seizure control (PSC) over those with IDH
wild type. However, no association of PSC was reported
with age, sex, extent of surgery, glioma grade, location and
histopathological subtype, p53 expression, ARTX retention,
or 1p/19q co-deletion status. Larger longitudinal studies
were suggested for better evidence and customizing
treatment strategies accordingly.5 In a secondary analysis
of a previously published multi-center randomized control
trial of 562 elderly glioblastoma patients in 2020, Climans
et al., examined seizure outcomes in patients undergoing
chemotherapy with temozolomide plus short-course
radiotherapy versus those undergoing radiotherapy alone.
Almost all patients were followed until they died. In the
radiotherapy alone group, 68 (24%) patients had a
documented or self-reported post-operative seizure versus
83 (30%) patients in the temozolomide plus radiotherapy
group (p=0.15). Shorter seizure free interval was also seen
in the only-radiotherapy group of patients (p=0.054). These
results, while not statistically significant, were suggested
to be used as a basis for better longitudinal studies
especially powered to detect differences in seizure
outcomes, as they did provide some evidence in
temozolomide’s minimal impact on seizure control in
glioblastoma patients.10
Compared to conventional gross-total resections (GTR),
supra-total resection of glioblastoma in terms of anterior
temporal lobectomy (ATL) has gained growing popularity
within the neurosurgical field. In a retrospective study
published in 2021, Borger et al., evaluated 33 glioblastoma
patients with pre-operative seizures, undergoing GTR or
ATL. While 23 patients overall achieved favourable seizure
outcomes (International League Against Epilepsy - ILAE -
class 1) postoperatively, seizure freedom was achieved in
100% patients in the ATL cohort, vs 50% patients in the GTR
cohort (p=0.002).11
Figure-2: Axial section of T1-post contrast image of the same patient showing ring
enhancing cystic lesion in the right temporal lobe. The patient under-
went surgical resection of this lesion, and histopathology was reported
as glioblastoma.
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Conclusion
Seizure freedom is one of the goals in the treatment of
glioblastoma patients with epilepsy. While AED treatment
should be started, it should be realized that a significant
percentage of patients will still have seizures despite
therapeutic levels of AEDs. Polytherapy with AEDs, supra-
total resection of the lesion, chemotherapy with
temozolomide, and targeted molecular therapy may play
a role in improving patient outcomes.
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